Nmda Neurotransmission Dysfunction in mild cognitive impairment and Alzheimer’s Disease

Current Pharmaceutical Design

Volumn 20, Issue 32, 2014, Pages 5169-5179

  Lin, Chieh Hsin ^a,b   Huang, Yu Jhen ^a   Lin, Chun Jung ^a   Lane, Hsien Yuan ^a   Tsai, Guochuan E ^c,d  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d Los Angeles Biomedical Research Institute   (United States)

Author keywords

Alzheimer s disease; Glutamate; Mild cognitive impairment; NMDA

Indexed keywords

ACETYLCHOLINE; AMYLOID; CYCLOSERINE; DEXTRO SERINE; GLUTAMIC ACID; GLYCINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROTRANSMITTER; TAU PROTEIN; N METHYLASPARTIC ACID;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; CLINICAL TRIAL (TOPIC); COGNITION; COGNITIVE DEFECT; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; EARLY INTERVENTION; FRUIT FLY MODEL; HUMAN; IN VITRO STUDY; MEMORY; MILD COGNITIVE IMPAIRMENT; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROPATHOLOGY; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PHARMACEUTICAL CARE; PREVALENCE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RODENT MODEL; SCHIZOPHRENIA; AGED; AGING; ANIMAL; BRAIN; DISEASE MODEL; DRUG DESIGN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

AGED; AGING; ALZHEIMER DISEASE; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DRUG DESIGN; HUMANS; MILD COGNITIVE IMPAIRMENT; N-METHYLASPARTATE; NEURONAL PLASTICITY; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPTIC TRANSMISSION;

EID: 84920769781     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612819666140110115603     Document Type: Article

References (176)

1. [1] Promoting brain health. Centers for Disease Control and Prevention. (http://www.cdc.gov/aging/pdf/cognitive_impairment/cogImp_gen Aud_final.pdf) 2011.
2. [2] Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. The Lancet 2005; 366: 2112-2117.
3. [3] Organization WH. The World Health Report 2003-Shaping the future. 2003.
4. [4] Thies W, Bleiler L. 2011 Alzheimer's disease facts and figures. Alzheimers Dement 2011; 7: 208-44.
5. [5] Ritchie K, Kildea D. Is senile dementia "age-related" or "ageingrelated"?--evidence from meta-analysis of dementia prevalence in the oldest old. Lancet 1995; 346: 931-4.
6. [6] Holtzman DM, Morris JC, Goate AM. Alzheimer's Disease: The Challenge of the Second Century. Sci. Transl. Med 2011; 3.
7. [7] Levey A, Lah J, Goldstein F, Steenland K, Bliwise D. Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease. Clin Ther 2006; 28: 991-1001.
8. [8] Bowen J, Teri L, Kukull W, McCormick W, McCurry SM, Larson EB. Progression to dementia in patients with isolated memory loss. Lancet 1997; 349: 763-5.
9. [9] Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004; 256: 240-6.
10. [10] Boeve BF. Mild cognitive impairment associated with underlying Alzheimer's disease versus Lewy body disease. Parkinsonism Relat Disord 2012; 18 Suppl 1: S41-4.
11. [11] Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-8.
12. [12] Deutsch JA. The cholinergic synapse and the site of memory. Science 1971; 174: 788-94.
13. [13] Blokland A. Acetylcholine: a neurotransmitter for learning and memory? Brain Res Brain Res Rev 1995; 21: 285-300.
14. [14] Patel S, Tariot PN. Pharmacologic models of Alzheimer's disease. Psychiatr Clin North Am 1991; 14: 287-308.
15. [15] Katzman R, Brown T, Fuld P, Thal L, Davies P, Terry R. Significance of neurotransmitter abnormalities in Alzheimer's disease. Res Publ Assoc Res Nerv Ment Dis 1986; 64: 279-86.
16. [16] Schaeffer EL, Gattaz WF. Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme. Psychopharmacology (Berl) 2008; 198: 1-27.
17. [17] Bierer LM, Haroutunian V, Gabriel S, et al. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem 1995; 64: 749-60.
18. [18] Lleo A, Greenberg SM, Growdon JH. Current pharmacotherapy for Alzheimer's disease. Annu Rev Med 2006; 57: 513-33.
19. [19] Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006: CD005593.
20. [20] Burns A, O'Brien J, Auriacombe S, et al. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol 2006; 20: 732-55.
21. [21] Lanctot KL, Herrmann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003; 169: 557-64.
22. [22] Raschetti R, Maggini M, Sorrentino GC, Martini N, Caffari B, Vanacore N. A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. Eur J Clin Pharmacol 2005; 61: 361-8.
23. [23] Fellgiebel A. [Alzheimer drugs for mild cognitive impairment]. Neuropsychiatr 2007; 21: 230-3.
24. [24] Birks J, Flicker L. Donepezil for mild cognitive impairment. Cochrane Database Syst Rev 2006: CD006104.
25. [25] Schneider LS, Insel PS, Weiner MW. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. Arch Neurol 2011; 68: 58-66.
26. [26] Feldman HH, Ferris S, Winblad B, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007; 6: 501-12.
27. [27] Winblad B, Gauthier S, Scinto L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008; 70: 2024-35.
28. [28] O'Brien JT, Burns A. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol 2011; 25: 997-1019.
29. [29] Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010; 362: 329-44.
30. [30] Wang JZ, Liu F. Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol 2008; 85: 148-75.
31. [31] Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci USAUSA 1988; 85: 4051-5.
32. [32] Gotz J, Ittner A, Ittner LM. Tau-targeted treatment strategies in Alzheimer's disease. Br J Pharmacol 2012; 165: 1246-59.
33. [33] Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995; 16: 271-8; discussion 278-84.
34. [34] Nicholson AM, Methner DN, Ferreira A. Membrane cholesterol modulates {beta}-amyloid-dependent tau cleavage by inducing changes in the membrane content and localization of N-methyl-Daspartic acid receptors. J Biol Chem 2011; 286: 976-86.
35. [35] Roberson ED, Halabisky B, Yoo JW, et al. Amyloid-beta/Fyninduced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci 2011; 31: 700-11.
36. [36] Mattson MP. Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann N Y Acad Sci 2008; 1144: 97-112.
37. [37] Tilleux S, Hermans E. Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J Neurosci Res 2007; 85: 2059-70.
38. [38] Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994; 330: 613-22.
39. [39] Kalia LV, Kalia SK, Salter MW. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol 2008; 7: 742-55.
40. [40] McDonald JW, Johnston MV. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. Brain Res Brain Res Rev 1990; 15: 41-70.
41. [41] Miyamoto E. Molecular mechanism of neuronal plasticity: induction and maintenance of long-term potentiation in the hippocampus. J Pharmacol Sci 2006; 100: 433-42.
42. [42] Feldman DE. The spike-timing dependence of plasticity. Neuron 2012; 75: 556-71.
43. [43] Parsons CG, Stoffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. Neuropharmacology 2007; 53: 699-723.
44. [44] Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998-1007.
45. [45] Hu NW, Ondrejcak T, Rowan MJ. Glutamate receptors in preclinical research on Alzheimer's disease: update on recent advances. Pharmacol Biochem Behav 2012; 100: 855-62.
46. [46] Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci 2010; 11: 682-96.
47. [47] Bordji K, Becerril-Ortega J, Nicole O, Buisson A. Activation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid-ss production. J Neurosci 2010; 30: 15927-42.
48. [48] Hoey SE, Williams RJ, Perkinton MS. Synaptic NMDA receptor activation stimulates alpha-secretase amyloid precursor protein processing and inhibits amyloid-beta production. J Neurosci 2009; 29: 4442-60.
49. [49] Boric K, Munoz P, Gallagher M, Kirkwood A. Potential adaptive function for altered long-term potentiation mechanisms in aging hippocampus. J Neurosci 2008; 28: 8034-9.
50. [50] Ossowska K, Wolfarth S, Schulze G, et al. Decline in motor functions in aging is related to the loss of NMDA receptors. Brain Res 2001; 907: 71-83.
51. [51] Liu P, Smith PF, Darlington CL. Glutamate receptor subunits expression in memory-associated brain structures: regional variations and effects of aging. Synapse 2008; 62: 834-41.
52. [52] Yamada K, Nabeshima T. Changes in NMDA receptor/nitric oxide signaling pathway in the brain with aging. Microsc Res Tech 1998; 43: 68-74.
53. [53] Olney JW, Wozniak DF, Farber NB. Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies. Arch Neurol 1997; 54: 1234-40.
54. [54] Segovia G, Porras A, Del Arco A, Mora F. Glutamatergic neurotransmission in aging: a critical perspective. Mech Ageing Dev 2001; 122: 1-29.
55. [55] Riederer P, Hoyer S. From benefit to damage. Glutamate and advanced glycation end products in Alzheimer brain. J Neural Transm 2006; 113: 1671-7.
56. [56] Martinez M, Frank A, Diez-Tejedor E, Hernanz A. Amino acid concentrations in cerebrospinal fluid and serum in Alzheimer's disease and vascular dementia. J Neural Transm Park Dis Dement Sect 1993; 6: 1-9.
57. [57] Lowe SL, Bowen DM, Francis PT, Neary D. Ante mortem cerebral amino acid concentrations indicate selective degeneration of glutamate-enriched neurons in Alzheimer's disease. Neuroscience 1990; 38: 571-7.
58. [58] Cowburn R, Hardy J, Roberts P, Briggs R. Regional distribution of pre-and postsynaptic glutamatergic function in Alzheimer's disease. Brain Res 1988; 452: 403-7.
59. [59] Hashimoto K, Fukushima T, Shimizu E, et al. Possible role of Dserine in the pathophysiology of Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 385-8.
60. [60] Procter AW, Wong EH, Stratmann GC, Lowe SL, Bowen DM. Reduced glycine stimulation of [3H]MK-801 binding in Alzheimer's disease. J Neurochem 1989; 53: 698-704.
61. [61] Gordon-Krajcer W, Salinska E, Lazarewicz JW. N-methyl-daspartate receptor-mediated processing of beta-amyloid precursor protein in rat hippocampal slices: in vitro--superfusion study. Folia Neuropathol 2002; 40: 13-7.
62. [62] Lesne S, Ali C, Gabriel C, et al. NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production. J Neurosci 2005; 25: 9367-77.
63. [63] Uhasz GJ, Barkoczi B, Vass G, et al. Fibrillar Abeta (1-42) enhances NMDA receptor sensitivity via the integrin signaling pathway. J Alzheimers Dis 2010; 19: 1055-67.
64. [64] Alberdi E, Sanchez-Gomez MV, Cavaliere F, et al. Amyloid beta oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium 2010; 47: 264-72.
65. [65] Ando K, Uemura K, Kuzuya A, et al. N-cadherin regulates p38 MAPK signaling via association with JNK-associated leucine zipper protein: implications for neurodegeneration in Alzheimer disease. J Biol Chem 2011; 286: 7619-28.
66. [66] Marcello E, Gardoni F, Mauceri D, et al. Synapse-associated protein-97 mediates alpha-secretase ADAM10 trafficking and promotes its activity. J Neurosci 2007; 27: 1682-91.
67. [67] Kamenetz F, Tomita T, Hsieh H, et al. APP processing and synaptic function. Neuron 2003; 37: 925-37.
68. [68] Cisse M, Halabisky B, Harris J, et al. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 2011; 469: 47-52.
69. [69] Yamin G. NMDA receptor-dependent signaling pathways that underlie amyloid beta-protein disruption of LTP in the hippocampus. Journal of Neuroscience Research 2009; 87: 1729-36.
70. [70] Chen QS, Wei WZ, Shimahara T, Xie CW. Alzheimer amyloid beta-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus. Neurobiol Learn Mem 2002; 77: 354-71.
71. [71] Wang Q, Rowan MJ, Anwyl R. Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J Neurosci 2004; 24: 6049-56.
72. [72] Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 2004; 24: 3370-8.
73. [73] Wang Q, Wu J, Rowan MJ, Anwyl R. Beta-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. Eur J Neurosci 2005; 22: 2827-32.
74. [74] Kurup P, Zhang Y, Xu J, et al. Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61. J Neurosci 2010; 30: 5948-57.
75. [75] Goto Y, Niidome T, Akaike A, Kihara T, Sugimoto H. Amyloid beta-peptide preconditioning reduces glutamate-induced neurotoxicity by promoting endocytosis of NMDA receptor. Biochem Biophys Res Commun 2006; 351: 259-65.
76. [76] Zhao D, Watson JB, Xie CW. Amyloid beta prevents activation of calcium/calmodulin-dependent protein kinase II and AMPA receptor phosphorylation during hippocampal long-term potentiation. J Neurophysiol 2004; 92: 2853-8.
77. [77] Knobloch M, Farinelli M, Konietzko U, Nitsch RM, Mansuy IM. Abeta oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms. J Neurosci 2007; 27: 7648-53.
78. [78] Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDAtype glutamate receptor-dependent signaling pathway. Journal of Neuroscience 2007; 27: 2866-75.
79. [79] Amadoro G, Ciotti MT, Costanzi M, Cestari V, Calissano P, Canu N. NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation. Proc Natl Acad Sci USAUSA 2006; 103: 2892-7.
80. [80] Couratier P, Lesort M, Sindou P, Esclaire F, Yardin C, Hugon J. Modifications of neuronal phosphorylated tau immunoreactivity induced by NMDA toxicity. Mol Chem Neuropathol 1996; 27: 259-73.
81. [81] Sato S, Xu J, Okuyama S, et al. Spatial learning impairment, enhanced CDK5/p35 activity, and downregulation of NMDA receptor expression in transgenic mice expressing tau-tubulin kinase 1. J Neurosci 2008; 28: 14511-21.
82. [82] Ittner LM, Ke YD, Delerue F, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010; 142: 387-97.
83. [83] Chohan MO, Iqbal K. From tau to toxicity: emerging roles of NMDA receptor in Alzheimer's disease. J Alzheimers Dis 2006; 10: 81-7.
84. [84] Esclaire F, Lesort M, Blanchard C, Hugon J. Glutamate toxicity enhances tau gene expression in neuronal cultures. J Neurosci Res 1997; 49: 309-18.
85. [85] Rahman A, Ting K, Cullen KM, Braidy N, Brew BJ, Guillemin GJ. The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS One 2009; 4: e6344.
86. [86] Fleming LM, Johnson GV. Modulation of the phosphorylation state of tau in situ: the roles of calcium and cyclic AMP. Biochem J 1995; 309 (Pt 1): 41-7.
87. [87] Li L, Sengupta A, Haque N, Grundke-Iqbal I, Iqbal K. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett 2004; 566: 261-9.
88. [88] Allyson J, Dontigny E, Auberson Y, Cyr M, Massicotte G. Blockade of NR2A-containing NMDA receptors induces Tau phosphorylation in rat hippocampal slices. Neural Plast 2010; 2010: 340168.
89. [89] Yeung LY, Wai MS, Fan M, et al. Hyperphosphorylated tau in the brains of mice and monkeys with long-term administration of ketamine. Toxicol Lett 2010; 193: 189-93.
90. [90] Thornton C, Bright NJ, Sastre M, Muckett PJ, Carling D. AMPactivated protein kinase (AMPK) is a tau kinase, activated in response to amyloid beta-peptide exposure. Biochem J 2011; 434: 503-12.
91. [91] Fan H, Gao J, Wang W, Li X, Xu T, Yin X. Expression of NMDA receptor and its effect on cell proliferation in the subventricular zone of neonatal rat brain. Cell Biochem Biophys 2012; 62: 305-16.
92. [92] Mochizuki N, Takagi N, Kurokawa K, et al. Effect of NMDA receptor antagonist on proliferation of neurospheres from embryonic brain. Neurosci Lett 2007; 417: 143-8.
93. [93] Karmarkar SW, Bottum KM, Krager SL, Tischkau SA. ERK/MAPK is essential for endogenous neuroprotection in SCN2.2 cells. PLoS One 2011; 6: e23493.
94. [94] Esposito S, Pristera A, Maresca G, et al. Contribution of serine racemase/d-serine pathway to neuronal apoptosis. Aging Cell 2012.
95. [95] Huang X, Kong H, Tang M, Lu M, Ding JH, Hu G. D-Serine regulates proliferation and neuronal differentiation of neural stem cells from postnatal mouse forebrain. CNS Neurosci Ther 2012; 18: 4-13.
96. [96] Davidson ME, Kerepesi LA, Soto A, Chan VT. D-Serine exposure resulted in gene expression changes implicated in neurodegenerative disorders and neuronal dysfunction in male Fischer 344 rats. Arch Toxicol 2009; 83: 747-62.
97. [97] Procter AW, Stirling JM, Stratmann GC, Cross AJ, Bowen DM. Loss of glycine-dependent radioligand binding to the N-methyl-Daspartate-phencyclidine receptor complex in patients with Alzheimer's disease. Neurosci Lett 1989; 101: 62-6.
98. [98] Chen RQ, Wang SH, Yao W, et al. Role of glycine receptors in glycine-induced LTD in hippocampal CA1 pyramidal neurons. Neuropsychopharmacology 2011; 36: 1948-58.
99. [99] Chessell IP, Procter AW, Francis PT, Bowen DM. D-cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl D-aspartate receptor-ionophore complex in Alzheimer brain. Brain Res 1991; 565: 345-8.
100. Kwon HB, Sabatini BL. Glutamate induces de novo growth of functional spines in developing cortex. Nature 2011; 474: 100-4.
101. Harada K, Nakato K, Yarimizu J, et al. A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazol e), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease. Eur J Pharmacol 2012; 685: 59-69.
102. Morris RG, Anderson E, Lynch GS, Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature 1986; 319: 774-6.
103. Majumder S, Caccamo A, Medina DX, et al. Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1beta and enhancing NMDA signaling. Aging Cell 2012; 11: 326-35.
104. Fradley RL, O'Meara GF, Newman RJ, Andrieux A, Job D, Reynolds DS. STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating. Behav Brain Res 2005; 163: 257-64.
105. Shimizu E, Tang YP, Rampon C, Tsien JZ. NMDA receptordependent synaptic reinforcement as a crucial process for memory consolidation. Science 2000; 290: 1170-4.
106. Nakazawa K, Quirk MC, Chitwood RA, et al. Requirement for hippocampal CA3 NMDA receptors in associative memory recall. Science 2002; 297: 211-8.
107. Jacobs SA, Tsien JZ. genetic overexpression of NR2B subunit enhances social recognition memory for different strains and species. PLoS One 2012; 7: e36387.
108. Tsai G, Ralph-Williams RJ, Martina M, et al. Gene knockout of glycine transporter 1: characterization of the behavioral phenotype. Proc Natl Acad Sci USAUSA 2004; 101: 8485-90.
109. Wu CL, Xia S, Fu TF, et al. Specific requirement of NMDA receptors for long-term memory consolidation in Drosophila ellipsoid body. Nat Neurosci 2007; 10: 1578-86.
110. Xia S, Miyashita T, Fu TF, et al. NMDA receptors mediate olfactory learning and memory in Drosophila. Curr Biol 2005; 15: 603-15.
111. Amano H, Maruyama IN. Aversive olfactory learning and associative long-term memory in Caenorhabditis elegans. Learn Mem 2011; 18: 654-65.
112. Pitkanen M, Sirvio J, MacDonald E, Niemi S, Ekonsalo T, Riekkinen P, Sr. The effects of D-cycloserine and MK-801 on the performance of rats in two spatial learning and memory tasks. Eur Neuropsychopharmacol 1995; 5: 457-63.
113. Pitkanen M, Sirvio J, MacDonald E, Ekonsalo T, Riekkinen P, Sr. The effects of d-cycloserine, a partial agonist at the glycine binding site, on spatial learning and working memory in scopolaminetreated rats. J Neural Transm Park Dis Dement Sect 1995; 9: 133-44.
114. Zajaczkowski W, Danysz W. Effects of D-cycloserine and aniracetam on spatial learning in rats with entorhinal cortex lesions. Pharmacol Biochem Behav 1997; 56: 21-9.
115. Riekkinen M, Riekkinen P, Jr. Nicotine and D-cycloserine enhance acquisition of water maze spatial navigation in aged rats. Neuroreport 1997; 8: 699-703.
116. Aura J, Riekkinen M, Riekkinen P, Jr. Tetrahydroaminoacridine and D-cycloserine stimulate acquisition of water maze spatial navigation in aged rats. Eur J Pharmacol 1998; 342: 15-20.
117. Riekkinen P, Jr., Ikonen S, Riekkinen M. Tetrahydroaminoacridine, a cholinesterase inhibitor, and D-cycloserine, a partial NMDA receptor-associated glycine site agonist, enhances acquisition of spatial navigation. Neuroreport 1998; 9: 1633-7.
118. Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998; 44: 1081-9.
119. Gelfin E, Kaufman Y, Korn-Lubetzki I, et al. D-serine adjuvant treatment alleviates behavioural and motor symptoms in Parkinson's disease. Int J Neuropsychopharmacol 2012; 15: 543-9.
120. Wallace TL, Ballard TM, Pouzet B, Riedel WJ, Wettstein JG. Drug targets for cognitive enhancement in neuropsychiatric disorders. Pharmacol Biochem Behav 2011; 99: 130-45.
121. Randolph C, Roberts JW, Tierney MC, Bravi D, Mouradian MM, Chase TN. D-cycloserine treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 1994; 8: 198-205.
122. Fakouhi TD, Jhee SS, Sramek JJ, et al. Evaluation of cycloserine in the treatment of Alzheimer's disease. J Geriatr Psychiatry Neurol 1995; 8: 226-30.
123. Schwartz BL, Hashtroudi S, Herting RL, Schwartz P, Deutsch SI. d-Cycloserine enhances implicit memory in Alzheimer patients. Neurology 1996; 46: 420-4.
124. Tsai GE, Falk WE, Gunther J, Coyle JT. Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. Am J Psychiatry 1999; 156: 467-9.
125. Laake K, Oeksengaard AR. D-cycloserine for Alzheimer's disease. Cochrane Database Syst Rev 2002: CD003153.
126. Tsai GE, Lin PY. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des 2010; 16: 522-37.
127. Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol 2003; 2: 539-47.
128. Gardoni F, Mauceri D, Malinverno M, et al. Decreased NR2B subunit synaptic levels cause impaired long-term potentiation but not long-term depression. J Neurosci 2009; 29: 669-77.
129. Pallàs M, Camins A. Molecular and Biochemical Features in Alzheimer disease. Current Pharmaceutical Design 2006; 12.
130. Reisberg B, Doody R, Stöffler B, Schmitt F, Ferris S, Möbius HJ. Memantine in Moderate-to-Severe Alzheimer Disease. New England Journal of Medicine 2003; 348.
131. Riepe MW, Adler G, Ibach B, Weinkauf B, Gunay I, Tracik F. Adding memantine to rivastigmine therapy in patients with mild-tomoderate alzheimer's disease: results of a 12-week, open-label pilot study. Prim Care Companion J Clin Psychiatry 2006; 8: 258-63.
132. Peters O, Lorenz D, Fesche A, et al. A Combination of Galantamine and Memantine Modifies Cognitive Function in Subjects with Amnestic MCI. J Nutr Health Aging 2012; 16: 544-8.
133. Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, doubleblind, placebo-controlled 6-month study. J Alzheimers Dis 2008; 13: 97-107.
134. Cosman KM, Boyle LL, Porsteinsson AP. Memantine in the treatment of mild-to-moderate Alzheimer's disease. Expert Opin Pharmacother 2007; 8: 203-14.
135. Schneider LS, Dagerman KS, Higgins JP, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 2011; 68: 991-8.
136. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, doubleblind, placebo-controlled trial. Curr Alzheimer Res 2008; 5: 83-9.
137. Chen HS, Lipton SA. The chemical biology of clinically tolerated NMDA receptor antagonists. J Neurochem 2006; 97: 1611-26.
138. Yoon WJ, Won SJ, Ryu BR, Gwag BJ. Blockade of ionotropic glutamate receptors produces neuronal apoptosis through the Baxcytochrome C-caspase pathway: the causative role of Ca2+ deficiency. J Neurochem 2003; 85: 525-33.
139. Matsuoka N, Aigner TG. The glycine/NMDA receptor antagonist HA-966 impairs visual recognition memory in rhesus monkeys. Brain Res 1996; 731: 72-8.
140. van der Staay FJ, Rutten K, Erb C, Blokland A. Effects of the cognition impairer MK-801 on learning and memory in mice and rats. Behavioural Brain Research 2011; 220: 215-29.
141. Rowland LM, Astur RS, Jung RE, Bustillo JR, Lauriello J, Yeo RA. Selective cognitive impairments associated with NMDA receptor blockade in humans. Neuropsychopharmacology 2005; 30: 633-9.
142. Altamura AC, Bobo WV, Meltzer HY. Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. Int Clin Psychopharmacol 2007; 22: 249-67.
143. Chen WJ, Chang CH, Liu SK, Hwang TJ, Hwu HG. Sustained attention deficits in nonpsychotic relatives of schizophrenic patients: a recurrence risk ratio analysis. Biol Psychiatry 2004; 55: 995-1000.
144. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153: 321-30.
145. Goff DC, Tsai G, Levitt J, et al. A placebo-controlled trial of Dcycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999; 56: 21-7.
146. Javitt DC, Silipo G, Cienfuegos A, et al. Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol 2001; 4: 385-91.
147. Tsai G, Lane HY, Yang P, Chong MY, Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004; 55: 452-6.
148. Tsai GE, Yang P, Chang YC, Chong MY. D-alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2006; 59: 230-4.
149. Heresco-Levy U, Javitt DC, Ebstein R, et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 2005; 57: 577-85.
150. Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE. Sarcosine or Dserine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry 2005; 62: 1196-204.
151. Lin CH, Lane HY, Tsai GE. Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacol Biochem Behav 2012; 100: 665-77.
152. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999; 56: 29-36.
153. Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry 2004; 55: 165-71.
154. Lane HY, Lin CH, Huang YJ, Liao CH, Chang YC, Tsai GE. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol 2010; 13: 451-60.
155. Ingram DK, Spangler EL, Iijima S, et al. Rodent models of memory dysfunction in Alzheimer's disease and normal aging: moving beyond the cholinergic hypothesis. Life Sci 1994; 55: 2037-49.
156. Hetman M, Kharebava G. Survival signaling pathways activated by NMDA receptors. Curr Top Med Chem 2006; 6: 787-99.
157. Tremolizzo L, Beretta S, Ferrarese C. Peripheral markers of glutamatergic dysfunction in neurological diseases: focus on ex vivo tools. Crit Rev Neurobiol 2004; 16: 141-6.
158. Hashimoto K, Fukushima T, Shimizu E, et al. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 2003; 60: 572-6.
159. Rojas C, Stathis M, Polydefkis M, et al. Glutamate carboxypeptidase activity in human skin biopsies as a pharmacodynamic marker for clinical studies. J Transl Med 2011; 9: 27.
160. Nakki R, Koistinaho J, Sharp FR, Sagar SM. Cerebellar toxicity of phencyclidine. J Neurosci 1995; 15: 2097-108.
161. Rogers A, Schmuck G, Scholz G, Williams DC. c-fos mRNA expression in rat cortical neurons during glutamate-mediated excitotoxicity. Toxicol Sci 2004; 82: 562-9.
162. King AE, Chung RS, Vickers JC, Dickson TC. Localization of glutamate receptors in developing cortical neurons in culture and relationship to susceptibility to excitotoxicity. J Comp Neurol 2006; 498: 277-94.
163. Farinelli M, Heitz FD, Grewe BF, Tyagarajan SK, Helmchen F, Mansuy IM. Selective regulation of NR2B by protein phosphatase-1 for the control of the NMDA receptor in neuroprotection. PLoS One 2012; 7: e34047.
164. Nakanishi N, Tu S, Shin Y, et al. Neuroprotection by the NR3A subunit of the NMDA receptor. J Neurosci 2009; 29: 5260-5.
165. Zhu D, Wu X, Strauss KI, et al. N-methyl-D-aspartate and TrkB receptors protect neurons against glutamate excitotoxicity through an extracellular signal-regulated kinase pathway. J Neurosci Res 2005; 80: 104-13.
166. Chuang DM. The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials. Ann N Y Acad Sci 2005; 1053: 195-204.
167. Caldero J, Brunet N, Tarabal O, et al. Lithium prevents excitotoxic cell death of motoneurons in organotypic slice cultures of spinal cord. Neuroscience 2010; 165: 1353-69.
168. Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry 2011; 198: 351-6.
169. Zhang XZ, Li XJ, Zhang HY. Valproic acid as a promising agent to combat Alzheimer's disease. Brain Res Bull 2010; 81: 3-6.
170. Tariot PN, Schneider LS, Cummings J, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry 2011; 68: 853-61.
171. Dolga AM, Nijholt IM, Ostroveanu A, Ten Bosch Q, Luiten PG, Eisel UL. Lovastatin induces neuroprotection through tumor necrosis factor receptor 2 signaling pathways. J Alzheimers Dis 2008; 13: 111-22.
172. Chandrasekaran K, Mehrabian Z, Spinnewyn B, Chinopoulos C, Drieu K, Fiskum G. Bilobalide, a component of the Ginkgo biloba extract (EGb 761), protects against neuronal death in global brain ischemia and in glutamate-induced excitotoxicity. Cell Mol Biol (Noisy-le-grand) 2002; 48: 663-9.
173. Kataria H, Wadhwa R, Kaul SC, Kaur G. Water Extract from the Leaves of Withania somnifera Protect RA Differentiated C6 and IMR-32 Cells against Glutamate-Induced Excitotoxicity. PLoS One 2012; 7: e37080.
174. Wei L, Ge L, Qin S, et al. Hydrogen-rich saline protects retina against glutamate-induced excitotoxic injury in guinea pig. Exp Eye Res 2012; 94: 117-27.
175. Sureda FX, Gabriel C, Pallas M, et al. In vitro and in vivo protective effect of orphenadrine on glutamate neurotoxicity. Neuropharmacology 1999; 38: 671-7.
176. Thorns V, Masliah E. Evidence for neuroprotective effects of acidic fibroblast growth factor in Alzheimer disease. J Neuropathol Exp Neurol 1999; 58: 296-306.